Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Integrated omics approaches to infectious diseases / / Saif Hameed and Zeeshan Fatima (editors)
| Integrated omics approaches to infectious diseases / / Saif Hameed and Zeeshan Fatima (editors) |
| Pubbl/distr/stampa | Gateway East, Singapore : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (538 pages) |
| Disciplina | 616.9 |
| Soggetto topico |
Parasitology
Communicable diseases - Etiology Malalties infeccioses Etiologia Biologia molecular Nanomedicina |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-16-0691-9 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910495232703321 |
| Gateway East, Singapore : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Nanotechnology for infectious diseases / / edited by Saif Hameed and Suriya Rehman
| Nanotechnology for infectious diseases / / edited by Saif Hameed and Suriya Rehman |
| Pubbl/distr/stampa | Gateway East, Singapore : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (638 pages) |
| Disciplina | 616.90475 |
| Soggetto topico | Nanomedicine |
| ISBN |
981-16-9190-8
981-16-9189-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Foreword by Dr. Shahid Jameel -- Foreword by Prof. Abdulhadi Baykal -- Preface -- Contents -- About the Editors -- Part I: Infectious Diseases -- 1: A Holistic View of Human Infectious Diseases: Challenges and Opportunities -- 1.1 Overview -- 1.2 Chain of Infection -- 1.2.1 Infectious Agents -- 1.2.2 Reservoir -- 1.2.3 Modes of Escape -- 1.2.4 Mode of Transmission -- 1.2.5 Direct Contact -- 1.2.5.1 Droplet Transmission -- 1.2.5.2 Indirect Transmission -- Airborne Transmission -- Vehicle Borne Transmission -- Vector Borne Transmission -- 1.2.6 Portal of Entry -- 1.2.7 Susceptible Host -- 1.3 Emerging and Re-emerging Diseases -- 1.3.1 Re-emerging Infectious Diseases -- 1.3.2 Factors Contributing to Emergence or Re-emergence of Infectious Diseases -- 1.3.3 Globalization, Trade, and Travelling -- 1.3.4 Environmental and Ecological Changes -- 1.3.5 Human-Reservoir (Wild Animal) Interface -- 1.3.6 Adaptations and Changes of Microbial Agents/Antibiotic Resistance -- 1.4 Interventions for Infectious Disease Control and Prevention -- 1.4.1 Antimicrobials/Antibiotics -- 1.4.2 Vaccines -- 1.4.3 Public Health Priority for Infection Control -- 1.5 New Strategies and Hopes -- 1.5.1 Nanotechnology and Nanobiology -- 1.5.2 Gene Sequencing to Inform Infection Control -- 1.5.3 Data Handling and Simulation Systems -- 1.5.4 Healthcare Reforms -- 1.6 Conclusion -- References -- 2: Application of Nanotechnology in the Treatment of Infectious Diseases: An Overview -- 2.1 Introduction -- 2.2 Nano Formulations for the Treatment of Bacterial Infections -- 2.3 Nano Formulations for the Treatment of Fungal Infections -- 2.4 Application of Nanotechnology Against Viral Infections -- 2.5 Nanotechnology in Drug Delivery Targeting Infectious Diseases -- 2.6 Nanomaterials Vaccines for Infectious Diseases.
2.7 Nanomaterials in Photothermal Therapy Against Infectious Pathogens -- 2.8 Application of Nanodiamonds in Infectious Diseases -- 2.9 Synergistic Antimicrobial Potentials of Nanomaterials/Nanocomposite in Combination with Other Antimicrobial Agents Against... -- 2.10 Challenges and Future Perspectives -- 2.11 Conclusion -- References -- 3: Understanding the Pharmacology and Pharmacotherapeutics for Infectious Diseases -- 3.1 Introduction -- 3.2 Transmission of Infectious Diseases -- 3.3 Infectious Diseases -- 3.3.1 Bacterial Diseases -- 3.3.2 Fungal Infections -- 3.3.3 Viral Infections -- 3.3.4 Parasitic Infections -- 3.4 Emerging Infectious Diseases -- 3.5 Pharamacotherapeutic Interventions -- 3.5.1 Antibiotics -- 3.5.1.1 Beta Lactam Antibiotics -- 3.5.1.2 Fluoroquinolones -- 3.5.2 Antifungals -- 3.5.3 Antivirals -- 3.5.3.1 Antiviral Targeting the Viral Proteins -- 3.5.3.2 Antivirals Targeting the Host Proteins -- 3.5.4 Antiparasitic Drugs -- 3.6 Nanomedicine -- 3.6.1 Types of Nanoparticles Used in Nanomedicine -- 3.6.1.1 Organic Nanoparticles -- 3.6.1.2 Inorganic Nanoparticles -- 3.6.2 Nanoparticles in Infectious Diseases -- 3.7 Conclusion -- References -- Part II: Nanomaterials as Anti-infection Therapeutics -- 4: Advanced Nanomaterials for Infectious Diseases Therapeutics -- 4.1 Metal-Based Nanoparticles -- 4.1.1 Silver Nanoparticles -- 4.1.2 Gold Nanoparticles -- 4.1.3 Iron-Oxide Based Nanoparticles -- 4.1.4 Zinc Oxide Nanoparticles -- 4.1.5 Copper Oxide Nanoparticles -- 4.2 Encapsulated Nanoparticles -- 4.2.1 Polymer/Dendrimer Encapsulation -- 4.2.2 Metal Encapsulation -- 4.3 Nanoantibiotics -- 4.4 Conclusions and Future Trend -- References -- 5: Metal-Based Nanoparticles for Infectious Diseases and Therapeutics -- 5.1 Introduction -- 5.2 Bacteria and Antibacterial Drug -- 5.3 Metal-Based Nanoparticles. 5.3.1 Synthesis, Characterization, and Properties of Metal-Based Nanoparticles -- 5.3.2 Classification of Metal-Based Nanoparticles -- 5.3.3 Metal Nanoparticles Against Infectious Diseases -- 5.3.4 Metal Oxide Nanoparticles Against Infectious Diseases -- 5.3.5 Metal Sulfide Nanoparticles Against Infectious Diseases -- 5.4 General Mechanism of Metal-Based Nanoparticles Against Infectious Diseases -- 5.5 Factors Affecting the Antimicrobial Activities of Nanoparticles -- 5.6 Conclusion -- References -- 6: The Future Therapy of Nanomedicine Against Respiratory Viral Infections -- 6.1 Introduction -- 6.2 Viruses Classification According to the Genetic Materials -- 6.3 The Threat of Respiratory Viral Infections -- 6.3.1 The SARS-CoV-2 Threat -- 6.3.2 Toxicity of Conventional Antiviral Drugs -- 6.4 Nanodrugs and Their Efficacy in Killing Viruses -- 6.4.1 Nanomedicine Weapon Against SARS-CoV-2 Threat -- 6.4.2 Biogenic and Non-biogenic Metallic Nanoparticles and Its Antiviral Efficiency -- 6.4.3 The Antiviral Activity of Organic Nanoparticles -- 6.4.3.1 Polymeric Nanoparticles -- 6.4.3.2 Carbon-Based Nanomaterials as Antivirals -- 6.4.3.3 Lactoferrin Loaded Nanoparticles as Antivirals -- 6.4.3.4 Silica Nanocarriers as Antivirals -- 6.5 Conclusion -- References -- 7: Application of Nanoparticles to Invasive Fungal Infections -- 7.1 Introduction -- 7.2 Antifungal Therapy -- 7.2.1 Azole Compounds -- 7.2.2 Pyrimidine Analogous -- 7.2.3 Polyenes -- 7.2.4 Echinocandins -- 7.3 Nanoformulations for Antifungal Therapy -- 7.3.1 Polymeric Nanoparticles -- 7.3.2 Metallic Nanoparticles -- 7.3.3 Lipid Nanoparticles -- 7.4 Systemic Mycoses and Nanotechnology -- 7.4.1 Candida sp. -- 7.4.1.1 Polymeric Nanoparticles -- 7.4.1.2 Lipid Nanoparticles -- 7.4.2 Aspergillus sp. -- 7.4.2.1 Polymeric Nanoparticles -- 7.4.3 Cryptococcus sp. -- 7.4.3.1 Polymeric Nanoparticles. 7.4.3.2 Metallic Nanoparticles -- 7.4.3.3 Lipid Nanoparticles -- 7.4.4 Paracoccidioides sp. -- 7.4.4.1 Polymeric Nanoparticles -- Polymeric Nanoparticles Used in Vaccines -- 7.4.4.2 Metallic Nanoparticles -- 7.4.4.3 Lipid Nanoparticles -- 7.5 Conclusion -- References -- 8: Nanomaterials in the Diagnosis and Treatment of Leishmaniasis -- 8.1 Introduction -- 8.2 Available Chemotherapeutic Drugs for Leishmaniasis -- 8.2.1 Pentavalent Antimonial -- 8.2.2 Pentamidine -- 8.2.3 Amphotericin B -- 8.2.4 Miltefosine -- 8.2.5 Paromomycin -- 8.2.6 Sitamaquine -- 8.2.7 Other New Antileishmanial Molecules -- 8.3 Conventional Methods for Detection of Leishmaniasis -- 8.4 Nanomaterials in the Diagnosis of Leishmaniasis -- 8.5 Nanomaterials in the Therapy and Protection Against Leishmania spp. Infection -- 8.5.1 Antileishmanial Nanoparticles and Nanopreparations -- 8.5.2 Nanomaterials in the Development of Vaccine Against Leishmaniasis -- 8.6 Conclusion -- References -- 9: A Comprehensive Review on the Synthesis, Surface Decoration of Nanoselenium and Their Medical Applications -- 9.1 Introduction -- 9.2 Chemical Synthesis of SeNPs -- 9.2.1 Chemical Reduction Methods -- 9.2.2 Wet Chemical Method -- 9.2.3 Hydrothermal Methods -- 9.2.4 Solvothermal Method -- 9.2.5 Sol-Gel Method -- 9.3 Physical Synthesis of SeNPs -- 9.3.1 Lser bltin -- 9.3.2 Microwave Irradiation Method -- 9.3.3 Sonochemical (Ultrasonic) -- 9.3.4 Gamma Radiation -- 9.3.5 Low Temperature Reactive Aerosol Processing -- 9.3.6 Heterogeneous Condensation Method -- 9.3.7 Ball Milling Method -- 9.4 Biological Synthesis of SeNPs -- 9.5 Antimicrobial Activity and Mechanism of SeNPs -- 9.6 Surface Decoration of SeNPs -- 9.6.1 5-Fluorouracil (5-FU) -- 9.6.2 Polyporus rhinoceros -- 9.6.3 Chitosan -- 9.6.4 Other Amino Acids -- 9.6.5 Proteins or Polypeptide -- 9.6.6 Natural Products -- 9.7 Conclusion -- References. Part III: Nanotechnology and Drug Carriers -- 10: Nanotechnology in Drug Delivery Systems: Ways to Boost Bioavailability of Drugs -- 10.1 Introduction -- 10.2 Nanotechnology Oriented Drug Delivery Systems -- 10.3 Nanoparticles as Drug Carrier -- 10.4 Quantum Dots Nanocarriers -- 10.5 Electrospun Nanofibers as Carriers -- 10.6 Nanoemulsions for Delivery of Drugs -- 10.7 Nanohydrogel Delivery Systems -- 10.8 Conclusion -- References -- 11: Recent Developments in Silica Nanoparticle Based Drug Delivery System -- 11.1 Introduction -- 11.2 Types of Silica Nanoparticles -- 11.3 Non-porous Silica Nanoparticle -- 11.4 Mesoporous Silica Nanoparticles -- 11.5 Core/Shell Silica Nanoparticles -- 11.6 Synthesis of Silica Nanoparticles -- 11.7 Mesoporous Silica Nanoparticles as Drug Delivery System -- 11.8 pH Responsive MSN Based Carrier System -- 11.9 Redox Responsive Nanocarrier -- 11.10 Enzyme Responsive Nanocarrier -- 11.11 Silica Nanoparticle as a DDS for Infectious Diseases -- 11.12 Beneficial Attributes of NPs for Treatment of Infectious Diseases -- 11.13 Specific Properties of MSN Due to Which they are Used as a Nanocarrier for Infectious Disease Treatment -- 11.14 Biocompatibility, Biodistribution, and Clearance of Silica Nanoparticles -- References -- 12: Nano Drug Delivery Approaches for Lymphatic Filariasis Therapeutics -- 12.1 Introduction -- 12.2 Pathophysiological Aspects of Lymphatic Filariasis and Drug Based Targeting -- 12.3 Nanomedicine as Advanced Tool for Targeting -- 12.3.1 Nanotechnology for Overcoming Anatomical Barriers -- 12.3.1.1 In the Treatment of Adult Stage Filariasis Through Targeted Nano Drug Delivery System -- 12.3.1.2 Nanotherapeutic Amplification of MIF Effectiveness to Stop the Conduction of Lymphatic Filariasis -- 12.3.2 Nanotechnology as Enhancing the Physiochemical Properties. 12.3.2.1 Nanoscientific Elucidation for Poor Solubility of Anti-filarial Agents. |
| Record Nr. | UNINA-9910743343003321 |
| Gateway East, Singapore : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Pathogenicity and Drug Resistance of Human Pathogens : Mechanisms and Novel Approaches / / edited by Saif Hameed, Zeeshan Fatima
| Pathogenicity and Drug Resistance of Human Pathogens : Mechanisms and Novel Approaches / / edited by Saif Hameed, Zeeshan Fatima |
| Edizione | [1st ed. 2019.] |
| Pubbl/distr/stampa | Singapore : , : Springer Singapore : , : Imprint : Springer, , 2019 |
| Descrizione fisica | 1 online resource (XXIV, 404 p. 52 illus., 43 illus. in color.) |
| Disciplina | 616.9041 |
| Soggetto topico |
Parasitology
Infectious diseases Drug resistance Bioinformatics Virology Infectious Diseases Drug Resistance Resistència als medicaments Patologia |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-329-449-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Module 1_Pathogenicity and Drug resistance in Mycobacterium tuberculosis -- Module 2_ Candida infections and therapeutic strategies -- Module 3_Malarial parasite biology -- Module 4_ Emerging Viral Diseases -- Module 5_Translational Research in Human Microbes. |
| Record Nr. | UNINA-9910373905103321 |
| Singapore : , : Springer Singapore : , : Imprint : Springer, , 2019 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||